We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $101.09 · 11 analysts
Stored first · Google News · Yahoo Finance (English)
Disc Medicine Investor News: If You Have Suffered Losses in - GlobeNewswire
Disc Medicine Investor News: If You Have Suffered Losses in GlobeNewswire
Cantor Fitzgerald reiterates Disc Medicine stock rating on pipeline catalysts - Investing.com
Cantor Fitzgerald reiterates Disc Medicine stock rating on pipeline catalysts Investing.com
Disc Medicine Insider Sold Shares Worth $2,473,780, According to a Recent SEC Filing
Disc Medicine CEO John Quisel sells $2.47m in shares - Investing.com
Disc Medicine CEO John Quisel sells $2.47m in shares Investing.com
Form 4 Disc Medicine Inc For: 14 July By Investing.com - Investing.com Canada
Form 4 Disc Medicine Inc For: 14 July By Investing.com Investing.com Canada
Form 144 Disc Medicine For: 13 July By Investing.com - Investing.com Nigeria
Form 144 Disc Medicine For: 13 July By Investing.com Investing.com Nigeria
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | After market close (AMC) | $-1.77 | — | — | $0 | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 15. | Morgan Stanley | — | Maintain | Overweight → Overweight | — | Morgan Stanley: Overweight |
| 2026. 03. 03. | Wells Fargo | — | Maintain | Overweight → Overweight | — | Wells Fargo: Overweight |
| 2026. 02. 28. | Truist Securities | — | Maintain | Buy → Buy | — | Truist Securities: Buy |
| 2026. 02. 18. | Stifel | — | Maintain | Buy → Buy | — | Stifel: Buy |
| 2026. 02. 18. | Cantor Fitzgerald | — | Maintain | Overweight → Overweight | — | Cantor Fitzgerald: Overweight |
| 2026. 02. 17. | BMO Capital | — | Maintain | Outperform → Outperform | — | BMO Capital: Outperform |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.